An interventional study of Social Media Message about HPV and HPV vaccine and Social media message about risk of electronic cigarettes. in Vaccine and Human Papilloma Virus, sponsored by Dartmouth-Hitchcock Medical Center. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2022-09-14.
Sponsored by Dartmouth-Hitchcock Medical Center · Not applicable, Interventional, and Health services research
This project involves a social media campaign to increase parent's knowledge and acceptance of the HPV (human papillomavirus) vaccine. The current vaccine protects against nine types of HPV, including seven that are known to cause cancer. The Centers for Disease Control and Prevention (CDC) estimates that the current HPV vaccine could prevent 90% of cancer cases caused by HPV, including cases of cervical cancer, oropharyngeal (mouth and throat) cancer, anal cancer, and others. About 150 and 104 cases of HPV-associated cancers are diagnosed each year in New Hampshire and Vermont, respectively-many of which could be prevented through vaccination. Currently, only 49.8% of New Hampshire adolescents and 44.3% of Vermont adolescents were not up-to-date for HPV vaccination as of 2016. This social media campaign is testing a set of campaign messages with parents locally and nationally to see which messages are most effective in improving their knowledge and acceptance of the vaccine. A study survey link will monitor the number of people reached and will measure parental intention to get their children vaccinated against HPV.
404 studies on the registry are indexed under Behavior; 167 are open to participants now.
This study's enrollment of 1,043 is above the median of 120 across 316 interventional studies indexed under Behavior.
Browse Behavior studies →Dartmouth-Hitchcock Medical Center is the lead sponsor of 486 studies on the registry; 69 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 21 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects are randomized to receive one of five messages on one of the four themes about HPV vaccination.
Other: Social Media Message about HPV and HPV vaccine
Subjects are randomized to receive one of five messages about electronic cigarettes.
Other: Social media message about risk of electronic cigarettes.
Messages educate parents with facts about HPV vaccination.
Messages educate parents with facts about electronic cigarettes. This is an attention control group without outcomes obtained.
Change in Attitudes About HPV Vaccine
Change in Attitudes about HPV vaccine: Pre to post test comparison of summated 9 items measured on a 7-point scale of HPV vaccine attitudes. Scores range from a minimum of 9 to a maximum of 63. Higher scores indicated more positive attitudes toward HPV vaccination. Change was calculated from two time points, the later time point(\<1 hour post messaging intervention) minus value at baseline.
Time frame: Post test completed < 1 hour post messaging intervention
Behavioral Intention to Vaccinate Their Child With HPV Vaccine
A sub-group of parents of 9-14 year old children who had not been vaccinated were asked on pre- and post-test: How likely is it that she/he will receive the HPV vaccine in the next 12 months? Responses range form 1 (very likely) to 5 (not very likely). HPV vaccination behavioral intent change scores were calculated by subtracting pre- and post- test values. It is a negative-value scale, in which smaller values indicate more positive attitude change after exposure to the viewed message.
Time frame: Ore test immediately before viewing message and post- test immediately after viewing message. Approximately one hour.
1713 prospective participants responded to a social media or MTurk posting about the study between 12/12/18 to 04/15/19. 39 declined to consent. Of the remaining 1674 participants: 631 had no child and were deemed ineligible,.1043 people were eligible and consented to be in the study. Of that, 45 dropped before random assignment. As such, 998 people were eligible, provided a consent, and completed a baseline survey.
| Milestone | HPV Messaging | Control Messaging |
|---|---|---|
| Started | 834 | 164 |
| Completed | 833 | 162 |
| Not completed | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 2 |
Change in Attitudes about HPV vaccine: Pre to post test comparison of summated 9 items measured on a 7-point scale of HPV vaccine attitudes. Scores range from a minimum of 9 to a maximum of 63. Higher scores indicated more positive attitudes toward HPV vaccination. Change was calculated from two time points, the later time point(\<1 hour post messaging intervention) minus value at baseline.
| units on a scale | HPV Messaging | Control Messaging |
|---|---|---|
| Change in Attitudes About HPV Vaccine | .16 ± .92 | -.08 ± .91 |
A sub-group of parents of 9-14 year old children who had not been vaccinated were asked on pre- and post-test: How likely is it that she/he will receive the HPV vaccine in the next 12 months? Responses range form 1 (very likely) to 5 (not very likely). HPV vaccination behavioral intent change scores were calculated by subtracting pre- and post- test values. It is a negative-value scale, in which smaller values indicate more positive attitude change after exposure to the viewed message.
| units on a scale | HPV Messaging | Control Message |
|---|---|---|
| Behavioral Intention to Vaccinate Their Child With HPV Vaccine | -.022 ± .81 | -.06 ± .92 |
Collected over Adverse events not anticipated over the < 1 hour of the study for a participant which only collects survey data about views of HPV vaccine. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HPV Messaging | — | — | — |
| Control Message | — | — | — |
1,713 participants initially recruited but 631 ineligible because no child leaving 1,043 eligible. Of eligibles 998 completed baseline survey.
| Age, Continuous(years) | HPV Messaging | Control Message | Total |
|---|---|---|---|
| Mean | 38.05 ± 10.75 | 37.33 ± 10.88 | 37.93 ± 10.77 |
| Sex: Female, Male(Participants) | HPV Messaging | Control Message | Total |
|---|---|---|---|
| Female | 520 | 96 | 616 |
| Male | 314 | 68 | 382 |
| Race and Ethnicity Not Collected(Participants) | HPV Messaging | Control Message | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Prior knowledge of HPV(Participants) | HPV Messaging | Control Message | Total |
|---|---|---|---|
| Count of participants | 730 | 142 | 872 |
| HPV Vaccine in prevents Cervical Cancer(units on a scale) | HPV Messaging | Control Message | Total |
|---|---|---|---|
| Mean | 2.53 ± 1.58 | 2.48 ± 1.50 | 2.52 ± 1.56 |
| HPV Vaccine in prevents Throat Cancer(units on a scale) | HPV Messaging | Control Message | Total |
|---|---|---|---|
| Mean | 2.26 ± 1.80 | 2.08 ± 1.81 | 2.23 ± 1.80 |
Documents are hosted by the registry — open the source record to download them.
Ran from Dec 2018 to primary completion in Sep 2019, 8 months.
Results were first posted in Sep 2022, 3 years after primary completion.
Of 235 non-industry interventional studies with no phase under Behavior, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 51. This study's 8 months is below that.
Counting every sponsor, half of 241 studies reached it within 20 months; a quarter within 7 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dartmouth-Hitchcock Medical Center →